Improvement of non-steroidal anti-inflammatory drug-induced gastrointestinal symptoms during proton pump inhibitor treatment: Are g-protein β3 subunit genotype, helicobacter pylori status, and environmental factors response modifiers?

Digestion

Volumn 84, Issue 4, 2011, Pages 289-298

  Holtmann, G ^a,b   Van Rensburg, C ^c   Schwan, T ^d   Sander, P ^d   Siffert, W ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Nycomed GmbH   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Dyspepsia; Gastrointestinal symptoms; GNB3; Non steroidal anti inflammatory drugs; Pantoprazole; Proton pump inhibitor

Indexed keywords

G PROTEIN BETA3 PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PANTOPRAZOLE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOATING; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; EPIGASTRIC PAIN; ERUCTATION; FEMALE; FLATULENCE; GALLSTONE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENDER; GENETIC ASSOCIATION; GENOTYPE; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; HYPERTENSIVE CRISIS; INFLUENZA; LIVER METASTASIS; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; METEORISM; MULTICENTER STUDY; NAUSEA; OSTEOARTHRITIS; PATIENT COMPLIANCE; POLYARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPONDYLOSIS; STOMACH DISEASE; STOMACH PAIN; TREATMENT DURATION; UPPER ABDOMINAL PAIN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGE FACTORS; AGED; ALCOHOL DRINKING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; SEX FACTORS; SMOKING;

EID: 80055006344     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000331468     Document Type: Article

References (31)

1. Laine L: The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Disord 2003; 3(suppl 4):S30-S39. (Pubitemid 37526948)
2. Scheiman JM: Balancing risks and benefits of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs. Gastroenterol Clin North Am 2009; 38: 305-314.
3. Farkouh ME, Greenberg BP: An evidencebased review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009; 103: 1227-1237.
4. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-292. (Pubitemid 36169245)
5. The Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678.
6. Siffert W: G Protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 2005; 56: 17-28. (Pubitemid 40299771)
7. Adam B, Liebregts T, Holtmann G: Mechanisms of disease: Genetics of functional gastrointestinal disorders - searching the genes that matter. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 102-110. (Pubitemid 46454796)
8. Weinstein LS, Chen M, Xie T, Liu J: Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci 2006; 27: 260-266.
9. Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, Hui AJ, Leung VK, Lee VW, Lai LH, Wong GL, Chow DK, To KF, Leung WK, Chiu PW, Lee YT, Lau JY, Chan HL, Ng EK, Sung JJ: Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet 2007; 369: 1621-1626. (Pubitemid 46710125)
10. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group: Cost effectiveness of COX-2-selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ 2009; 339:b2538 doi: 10/1136/bmj.b2538.
11. Garcia Rodriguez LA, Jick H: Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 769-772. (Pubitemid 24098698)
12. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B: Association of a human G-protein-3 subunit variant with hypertension. Nat Genet 1998; 18: 45-48. (Pubitemid 28027877)
13. Fallingborg J: Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999; 46: 183-196. (Pubitemid 29299969)
14. Mönnikes H, Doerfler H, Schmitt H, Berghöfer P, Heading R: Is the response of GERD patients to PPI therapy affected by the presence of IBS-like symptoms? Gastroenterology 2008; 134(suppl 1):A126.
15. Stupnicki T, Dietrich K, Gonzalez-Carro P, Straszak A, Terjung A, Thomas KB, Lühmann R, Fischer R: Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003; 68: 198-208. (Pubitemid 38250509)
16. Hawkey C, Talley NJ, Yeomans ND, Jones R, Sung JJ, Långström G, Naesdal J, Scheiman JM; NASA1 SPACE1 Study Group: Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100: 1028-1036. (Pubitemid 40769038)
17. Treharne GJ, Douglas KM, Iwaszko J, Panoulas VF, Hale ED, Mitton DL, Piper H, Erb N, Kitas GD: Polypharmacy among people with rheumatoid arthritis: The role of age, disease duration and comorbidity. Musculoskeletal Care 2007; 5: 175-190.
18. Rosskopf D, Manthey I, Siffert W: Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein-3 subunit. Pharmacogenetics 2002; 12: 209-220. (Pubitemid 34596785)
19. Kerkhof HJ, Lories RJ, Meulenbelt I, Jonsdottir I, Valdes AM, Arp P, Ingvarsson T, Jhamai M, Jonsson H, Stolk L, Thorleifsson G, Zhai G, Zhang F, Zhu Y, van der Breggen R, Carr A, Doherty M, Doherty S, Felson DT, Gonzalez A, Halldorsson BV, Hart DJ, Hauksson VB, Hofman A, Ioannidis JP, Kloppenburg M, Lane NE, Loughlin J, Luyten FP, Nevitt MC, Parimi N, Pols HA, Rivadeneira F, Slagboom EP, Styrkársdóttir U, Tsezou A, van de Putte T, Zmuda J, Spector TD, Stefansson K, Uitterlinden AG, van Meurs JB: A genome-wide association study identifies an osteoarthritis susceptibility locus on chromosome 7q22. Arthritis Rheum 2010; 62: 499-510.
20. Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130: 1377-1390.
21. De Vries DR, ter Linde JJ, van Herwaarden MA, Smout AJ, Samsom M: Gastroesophageal reflux disease is associated with the C825T polymorphism in the G-protein-3 subunit gene (GNB3). Am J Gastroenterol 2009; 104: 281-285.
22. Van Lelyveld N, Linde JT, Schipper M, Samsom M: Candidate genotypes associated with functional dyspepsia. Neurogastroenterol Motil 2008; 20: 767-773. (Pubitemid 351814389)
23. Holtmann G, Siffert W, Haag S, Mueller N, Langkafel M, Senf W, Zotz R, Talley NJ: Gprotein-3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004; 126: 971-979. (Pubitemid 38451168)
24. Camilleri CE, Carlson PJ, Camilleri M, Castillo EJ, Locke GR 3rd, Geno DM, Stephens DA, Zinsmeister AR, Urrutia R: A study of candidate genotypes associated with dyspepsia in a US community. Am J Gastroenterol 2006; 101: 581-592. (Pubitemid 43340936)
25. Oshima T, Nakajima S, Yokoyama T, Toyoshima F, Sakurai J, Tanaka J, Tomita T, Kim Y, Hori K, Matsumoto T, Miwa H: The Gprotein-3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med Genet 2010; 11: 13.
26. Tahara T, Arisawa T, Shibata T, Wang F, Nakamura M, Sakata M, Hirata I, Nakano H: Homozygous 825T allele of the GNB3 protein influences the susceptibility of Japanese to dyspepsia. Dig Dis Sci 2008; 53: 642-646. (Pubitemid 351317077)
27. Andresen V, Camilleri M, Kim HJ, Stephens DA, Carlson PJ, Talley NJ, Saito YA, Urrutia R, Zinsmeister AR : Is there an association between GN-3-C825T genotype and lower functional gastrointestinal disorders? Gastroenterology 2006; 130: 1985-1994. (Pubitemid 43816949)
28. Saito YA, Locke GR 3rd, Zimmerman JM, Holtmann G, Slusser JP, de Andrade M, Petersen GM, Talley NJ: A genetic association study of 5-HTT LPR and GN-3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 465-470. (Pubitemid 46905394)
29. Cheer SM, Prakash A, Faulds D, Lamb HM: Pantoprazole: An update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-133.
30. Van Rensburg C, Berghöfer P, Enns R, Dattani ID, Maritz JF, Gonzalez Carro P, Fischer R, Schwan T: Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. Curr Med Res Opin 2008; 24: 2009-2018.
31. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M: The placebo effect and its determinants in osteoarthritis: Meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 1716-1723.